Analysts at Chardan Capital Didn’t Change their “Buy” rating for Catalyst Biosciences (CBIO) with $75 Price Objective; 3 Analysts Are Bullish Och-Ziff Capital Management Group (OZM) Last Week

February 9, 2018 - By Shannon Black

Among 10 analysts covering Och-Ziff Capital Management Group (NYSE:OZM), 3 have Buy rating, 0 Sell and 7 Hold. Therefore 30% are positive. Och-Ziff Capital Management Group had 33 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Monday, September 25 by Jefferies. The firm has “Neutral” rating by Bank of America given on Tuesday, June 28. The firm has “Hold” rating given on Wednesday, June 28 by Jefferies. The firm has “Neutral” rating by JP Morgan given on Thursday, February 16. RBC Capital Markets maintained it with “Outperform” rating and $5 target in Thursday, July 21 report. Compass Point upgraded the shares of OZM in report on Tuesday, October 20 to “Buy” rating. The firm has “Hold” rating given on Wednesday, August 26 by Zacks. Compass Point upgraded Och-Ziff Capital Management Group LLC (NYSE:OZM) on Thursday, September 29 to “Buy” rating. Compass Point maintained the shares of OZM in report on Wednesday, November 4 with “Buy” rating. RBC Capital Markets maintained Och-Ziff Capital Management Group LLC (NYSE:OZM) rating on Wednesday, February 3. RBC Capital Markets has “Outperform” rating and $7 target. See Och-Ziff Capital Management Group LLC (NYSE:OZM) latest ratings:

04/10/2017 Broker: Jefferies Rating: Hold Old Target: $3 New Target: $3.5 Maintain
25/09/2017 Broker: Jefferies Rating: Hold New Target: $3.0 Maintain
04/09/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $3.25 Maintain

Among 4 analysts covering Catalyst Biosciences (CBIO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Biosciences has $75 highest and $10 lowest target. $31’s average target is 23.21% above currents $25.16 stock price. Catalyst Biosciences had 5 analyst reports since June 6, 2017 according to SRatingsIntel. Chardan Capital Markets maintained it with “Buy” rating and $75 target in Friday, February 9 report.

Och-Ziff Capital Management Group LLC is a publicly owned hedge fund sponsor. The company has market cap of $1.02 billion. The firm provides investment advisory services for its clients. It has a 28.72 P/E ratio. It primarily caters to institutional investors which include pension funds, fund-of-funds, foundations and endowments, firms and other institutions, private banks and family offices.

Investors sentiment decreased to 1.07 in 2017 Q3. Its down 0.45, from 1.52 in 2017Q2. It worsened, as 12 investors sold Och-Ziff Capital Management Group LLC shares while 15 reduced holdings. 11 funds opened positions while 18 raised stakes. 84.98 million shares or 0.51% more from 84.55 million shares in 2017Q2 were reported. Hotchkis And Wiley Cap Mgmt Ltd Co holds 0% or 60,283 shares in its portfolio. Abrams Capital Mgmt Limited Partnership holds 22.24M shares. Quinn Opportunity Partners Llc reported 0.68% in Och-Ziff Capital Management Group LLC (NYSE:OZM). Edge Wealth Management Llc holds 2,500 shares. Moors And Cabot has invested 0.01% in Och-Ziff Capital Management Group LLC (NYSE:OZM). Continental Advsr Limited Liability holds 2.15 million shares. Verity Asset holds 0.07% or 25,505 shares in its portfolio. 23,200 were reported by Guinness Asset Mngmt Limited. Commonwealth Equity has invested 0% in Och-Ziff Capital Management Group LLC (NYSE:OZM). Renaissance Limited Co invested 0% of its portfolio in Och-Ziff Capital Management Group LLC (NYSE:OZM). Spectrum Mngmt Gru reported 179 shares. Knott David M invested 0% in Och-Ziff Capital Management Group LLC (NYSE:OZM). Bourgeon Cap Mngmt Limited Liability Corporation has invested 0.04% in Och-Ziff Capital Management Group LLC (NYSE:OZM). Mountain Lake Investment Mngmt Lc holds 0.01% in Och-Ziff Capital Management Group LLC (NYSE:OZM) or 13,800 shares. Moreover, Kj Harrison Prns has 0.02% invested in Och-Ziff Capital Management Group LLC (NYSE:OZM) for 19,800 shares.

The stock decreased 0.44% or $0.01 during the last trading session, reaching $2.24. About 233,330 shares traded. Och-Ziff Capital Management Group LLC (NYSE:OZM) has declined 36.39% since February 9, 2017 and is downtrending. It has underperformed by 53.09% the S&P500.

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. The company has market cap of $160.20 million. The Company’s product pipeline includes marzeptacog alfa, a Factor VIIa variant that completed a Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with inhibitors. It currently has negative earnings. The firm also develops CB 2679d/ISU304, a Factor IX drug, which has completed preclinical studies for the prophylactic treatment of individuals with hemophilia B; and CB 2782, a pre-clinical anti-C3 protease program for the treatment of dry age-related macular degeneration.

Analysts await Catalyst Biosciences, Inc. (NASDAQ:CBIO) to report earnings on March, 14. They expect $-1.79 EPS, up 61.75% or $2.89 from last year’s $-4.68 per share. After $-1.34 actual EPS reported by Catalyst Biosciences, Inc. for the previous quarter, Wall Street now forecasts 33.58% negative EPS growth.